Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion

Journal of Investigative Dermatology

Volumn 133, Issue 2, 2013, Pages 545-552

  Donia, Marco ^a,b   Hansen, Morten ^a   Sendrup, Sarah L ^a   Iversen, Trine Zeeberg ^a   Ellebæk, Eva ^a   Andersen, Mads H ^a   Straten, Per Thor ^a   Svane, Inge Marie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGENICITY; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE THERAPY; TREATMENT RESPONSE;

EID: 84872616852     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.336     Document Type: Article

References (45)

1. Alexander-Miller MA, Leggatt GR, Berzofsky JA (1996) Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 9:4102-7
2. Andersen RS, Thrue CA, Junker N et al. (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72:1642-50
3. Anichini A, Mortarini R, Nonaka D et al. (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405-11
4. Aptsiauri N, Carretero R, Garcia-Lora A et al. (2008) Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727-33
5. Ascierto PA, Marincola FM (2011) Combination therapy: the next opportunity and challenge of medicine. J Transl Med 9:115
6. Balch CM, Gershenwald JE, Soong SJ et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
7. Besser MJ, Shapira-Frommer R, Treves AJ et al. (2009) Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-deplet-ing chemotherapy regimen in metastatic melanoma patients. J Immuno-ther 32:415-23
8. Besser MJ, Shapira-Frommer R, Treves AJ et al. (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16:2646-55
9. Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739-45
10. Carlsson B, Sadeghi A, Bengtsson M et al. (2008) Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semi-matched melanoma cell lines. J Immunother 31:633-43
11. Carrega P, Morandi B, Costa R et al. (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD1 6(-) cells and display an impaired capability to kill tumor cells. Cancer 112:863-75
12. Daud AI, DeConti RC, Andrews S et al. (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896-903
13. Donia M, Junker N, Ellebaek E et al. (2011) Characterization and comparison of 'Standard' and 'Young' tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol. (in press)
14. Dudley ME, Gross CA, Langhan MM et al. (2010) CD8+ enriched 'young' tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16:6122-31
15. Dudley ME, Wunderlich JR, Shelton TER et al. (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-42
16. Dudley ME, Yang JC, Sherry R et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative che-moradiation preparative regimens. J Clin Oncol 26:5233-9
17. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-60
18. Ellebæk E, Iversen TZ, Junker N et al. (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169
19. Hunder NN, Wallen H, Cao J et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-703
20. Itzhaki O, Hovav E, Ziporen Y et al. (2011) Establishment and large-scale expansion of minimally cultured 'young' tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 34:212-20
21. Joseph RW, Peddareddigari VR, Liu P et al. (2011) Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17:4882-91
22. Junker N, Kvistborg P, Køllgaard T et al. (2012) Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cell Immunol 273:1-9
23. Kageshita T, Hirai S, Ono T (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154:745-54
24. Kirkin AF, thor Straten P, Zeuthen J (1996) Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother 42:203-12
25. Kirkwood JM, Ernstoff MS, Trautman T et al. (1990) In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol 8:1070-82
26. Køllgaard T, van den Berg JH, Donia M et al. (2012) Eleventh international conference on progress in vaccination against cancer (PIVAC-11), 10-13 October 2011, Copenhagen, Denmark. Cancer Immunol Immunother 61:1349-53
27. Kortylewski M, Komyod W, Kauffmann ME et al. (2004) Interferon-gamma- mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 122:414-22
28. Maluish AE, Urba WJ, Longo DL et al. (1988) The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6:434-45
29. Mendez R, Aptsiauri N, Del Campo A et al. (2009) HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 58:1507-15
30. Muranski P, Restifo NP (2009) Adoptive immunotherapy of cancer using CD4 (+) T cells. Curr Opin Immunol 21:200-8
31. Nuchtern JG, Biddison WE, Klausner RD (1990) Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 343:74-6
32. Prieto PA, Durflinger KH, Wunderlich JR et al. (2010) Enrichment of CD8 + cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother 33:547-56
33. Propper DJ, Chao D, Braybrooke JP et al. (2003) Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 9:84-92
34. Quezada SA, Simpson TR, Peggs KS et al. (2010) Tumor-reactive CD4 (+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207:637-50
35. Robbins PF, El-Gamil M, Li YF et al. (2002) Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 169:6036-47
36. Rosenberg SA, Yang JC, Sherry RM et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-7
37. Schiller JH, Pugh M, Kirkwood JM et al. (1996) Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2:29-36
38. Schmid DA, Irving MB, Posevitz V et al. (2010) Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184:4936-46
39. Seliger B, Ruiz-Cabello F, Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101:249-76
40. Singer K, Gottfried E, Kreutz M et al. (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60:425-31
41. van Duinen SG, Ruiter DJ, Broecker EB et al. (1988) Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019-25
42. Vyas JM, Van der Veen AG, Ploegh HL (2008) The known unknowns of antigen processing and presentation. Nat Rev Immunol 8:607-18
43. Weidanz JA, Nguyen T, Woodburn T et al. (2006) Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 177:5088-97
44. Zaidi MR, Merlino G (2011) The two faces of interferon-{gamma} in cancer. Clin Cancer Res 17:6118-24
45. Zeh HJ III, Perry-Lalley D, Dudley ME et al. (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989-94